IOA-244

Phase 1Small molecule

IiOnctura

IOA-244 is one of 15 small molecule programs targeting Solid Tumor, Adult. It is currently in Phase 1.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Solid Tumor, AdultActive, not recruiting

Solid Tumor, AdultPhase 1

Active, not recruiting

Competition

Competitive Landscape

24 competitors in Solid Tumor, Adult

#DrugCompanyPhaseTrials

Keytruda

Merck & Co.

Phase 1

3 2

Imjudo

AstraZeneca

Phase 1

1 3

Imfinzi

AstraZeneca

Phase 1

1 4

Jakafi

Incyte

Phase 1

1 5

Kisqali

Novartis

Phase 1

1 6

Avastin

BBio-Thera Solutions

Phase 1

2 7

Alimta

GGynecologic Oncology Group

Phase 1

1 8

Platinol

MMcNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.

Phase 1

1 9

Herceptin

OOrganon and Co

Phase 1

1 10

Faslodex

FFresenius Kabi Oncology Ltd.

Phase 1

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q1 2028

Phase 1Active, not recruiting

Solid Tumor, Adult

NCT04328844

Clinical

Trials by Indication[1]

Solid Tumor, Adult1 trial

First-in-Human Dose Study of IOA-244 in Patients With Advanced or Metastatic Cancers

Active, not recruiting·IiOnctura·Phase 1·NCT04328844·210 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for IOA-244. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — IOA-244 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for IOA-244. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — iOnctura company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 1[1]
Company: IiOnctura

IOA-244

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q1 2028

Trials by Indication[1]

Solid Tumor, Adult1 trial

References

Drug Info

Quick Facts

Related News